Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

Complete loss or deletion of the long arm of chromosome 5 is frequent in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). The putative gene(s) deleted and responsible for the pathogenesis of these poor prognosis hematologic disorders remain controversial. This study is a comprehensive analysis of previously implicated and novel genes for epigenetic inactivation in AML and MDS. In 146 AML cases, methylation of CTNNA1 was frequent, and more common in AML patients with 5q deletion (31%) than those without 5q deletion (14%), whereas no methylation of other 5q genes was observed. In 31 MDS cases, CTNNA1 methylation was only found in high-risk MDS (>or=RAEB2), but not in low-risk MDS (<RAEB2), indicating that CTNNA1 methylation might be important in the transformation of MDS to AML. CTNNA1 expression was lowest in AML/MDS patients with CTNNA1 methylation, although reduced expression was found in some patients without promoter methylation. Repressive chromatin marks (H3K27me3) at the promoter were identified in CTNNA1-repressed AML cell lines and primary leukemias, with the most repressive state correlating with DNA methylation. These results suggest progressive, acquired epigenetic inactivation at CTNNA1, including histone modifications and promoter CpG methylation, as a component of leukemia progression in patients with both 5q- and non-5q- myeloid malignancies.

[1]  P. Fenaux,et al.  The role of lenalidomide in the management of myelodysplasia with del 5q , 2008, British journal of haematology.

[2]  Stephan Sauer,et al.  Chromatin signatures of pluripotent cell lines , 2006, Nature Cell Biology.

[3]  A. List,et al.  KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. , 2001, Leukemia research.

[4]  C. Bloomfield,et al.  Molecular cytogenetic characterization of the KG‐1 and KG‐1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization , 2003, Genes, chromosomes & cancer.

[5]  D. Teng,et al.  Localization of SMAD5 and its evaluation as a candidate myeloid tumor suppressor. , 1997, Cancer research.

[6]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[7]  Yongning Zhou,et al.  α-catenin expression is decreased in patients with gastric carcinoma , 2005 .

[8]  P. Nowell,et al.  Physical mapping of the minimal region of loss in 5q- chromosome. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Herman,et al.  Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. , 2008, Cancer research.

[10]  S. Nimer,et al.  Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Schoch,et al.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.

[12]  S. Nishizuka,et al.  Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. , 1996, Cancer research.

[13]  Y. Doki,et al.  E-Cadherin and α-Catenin Expression in Human Esophageal Cancer , 1994 .

[14]  T. Golub,et al.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.

[15]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[16]  D. Oscier,et al.  Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome , 1993 .

[17]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[18]  N. Zhao,et al.  Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Herman,et al.  Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia , 2005, Annals of Hematology.

[20]  N. Satoh,et al.  Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. , 1996, Gastroenterology.

[21]  M. Greaves,et al.  Divergent molecular phenotypes of KG1 and KG1a myeloid cell lines. , 1986 .

[22]  T. Haferlach,et al.  Discovery of epigenetically silenced genes in acute myeloid leukemias , 2007, Leukemia.

[23]  Z. Arbieva,et al.  Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. , 2000, Blood.

[24]  S. Natsugoe,et al.  α‐catenin is a significant prognostic factor than E‐cadherin in esophageal squamous cell carcinoma , 2007 .

[25]  J. Herman,et al.  p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. , 1999, Blood.

[26]  John Anastasi,et al.  Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. , 2007, Blood.

[27]  J. Issa,et al.  Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. , 2006, Haematologica.

[28]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[29]  Kelly M. McGarvey,et al.  Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. , 2006, Cancer research.

[30]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[32]  Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. , 2000 .

[33]  P. Mendes-da-Silva,et al.  Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma , 2000, Molecular pathology : MP.

[34]  B. Quesnel,et al.  Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. , 1998, Blood.

[35]  W. Hiddemann,et al.  Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q , 2005, Leukemia.

[36]  Michael F Clarke,et al.  Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation , 2007, Nature Medicine.

[37]  J. Zavadil,et al.  Smad5, a tumor suppressor candidate at 5q31.1, is hemizygously lost and not mutated in the retained allele in human leukemia cell line HL60 , 1997, Leukemia.

[38]  R. Larson,et al.  Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. , 1996, Blood.

[39]  J. Boultwood,et al.  The 5q-syndrome. , 1994, Blood.

[40]  A. Kasprzyk,et al.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.

[41]  J. Herman,et al.  E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  J. Herman,et al.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.

[43]  P. Guldberg,et al.  Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients , 2006, European journal of haematology.

[44]  M. Pfeilstöcker,et al.  Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. , 2001, Blood.

[45]  S. Nimer,et al.  The 5q- abnormality. , 1987, Blood.

[46]  C. Plass,et al.  Alterations of DNA methylation in hematologic malignancies. , 2002, Cancer letters.

[47]  D. Oscier,et al.  Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome. , 1993, Blood.

[48]  R. Liang,et al.  Hypermethylation of gene promoters in hematological neoplasia , 2002, Hematological oncology.